News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,562 Results
Type
Article (41190)
Company Profile (267)
Press Release (685091)
Multimedia
Podcasts (88)
Webinars (20)
Section
Business (204829)
Career Advice (2027)
Deals (35568)
Drug Delivery (121)
Drug Development (81495)
Employer Resources (173)
FDA (16476)
Job Trends (14972)
News (346754)
Policy (32765)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2585)
Accelerated approval (42)
Adcomms (25)
Allergies (160)
Alliances (49618)
ALS (192)
Alzheimer's disease (1740)
Antibody-drug conjugate (ADC) (368)
Approvals (16792)
Artificial intelligence (594)
Autoimmune disease (222)
Automation (50)
Bankruptcy (363)
Best Places to Work (11645)
BIOSECURE Act (20)
Biosimilars (201)
Biotechnology (176)
Bladder cancer (177)
Brain cancer (64)
Breast cancer (686)
Cancer (5315)
Cardiovascular disease (442)
Career advice (1716)
Career pathing (39)
CAR-T (299)
CDC (53)
Celiac Disease (2)
Cell therapy (797)
Cervical cancer (41)
Clinical research (70251)
Collaboration (1891)
Company closure (4)
Compensation (1275)
Complete response letters (69)
COVID-19 (2725)
CRISPR (98)
C-suite (974)
Cystic fibrosis (148)
Data (7040)
Decentralized trials (3)
Denatured (26)
Depression (153)
Dermatology (57)
Diabetes (549)
Diagnostics (6824)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (293)
Drug pricing (194)
Drug shortages (29)
Duchenne muscular dystrophy (266)
Earnings (91058)
Editorial (61)
Employer branding (21)
Employer resources (152)
Events (118386)
Executive appointments (1031)
FDA (19890)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1614)
Gene editing (210)
Generative AI (51)
Gene therapy (654)
GLP-1 (1017)
Government (4696)
Grass and pollen (6)
Guidances (396)
Healthcare (18925)
HIV (73)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (273)
Immuno-oncology (80)
Indications (157)
Infectious disease (3037)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (273)
Interviews (316)
IPO (16655)
IRA (50)
Job creations (3646)
Job search strategy (1429)
JPM (61)
Kidney cancer (18)
Labor market (92)
Layoffs (553)
Leadership (34)
Legal (7952)
Liver cancer (98)
Longevity (28)
Lung cancer (712)
Lymphoma (406)
Machine learning (52)
Management (59)
Manufacturing (918)
MASH (176)
Medical device (13852)
Medtech (13929)
Mergers & acquisitions (20072)
Metabolic disorders (1407)
mRNA (175)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (381)
Neuropsychiatric disorders (98)
Neuroscience (3128)
Neurotech (1)
NextGen: Class of 2026 (6530)
Non-profit (4525)
Now hiring (73)
Obesity (662)
Opinion (275)
Ovarian cancer (186)
Pain (227)
Pancreatic cancer (254)
Parkinson's disease (336)
Partnered (33)
Patents (552)
Patient recruitment (588)
Peanut (60)
People (59249)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21904)
Phase 2 (30927)
Phase 3 (23037)
Pipeline (7100)
Policy (302)
Postmarket research (2564)
Preclinical (9283)
Press Release (64)
Prostate cancer (279)
Psychedelics (49)
Radiopharmaceuticals (329)
Rare diseases (990)
Real estate (5961)
Recruiting (70)
Regulatory (24979)
Reports (54)
Research institute (2404)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (163)
Series A (267)
Series B (200)
Service/supplier (11)
Sickle cell disease (106)
Special edition (23)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3630)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (84)
The Weekly (60)
Vaccines (1054)
Venture capital (98)
Weight loss (421)
Women's health (109)
Worklife (19)
Date
Today (118)
Last 7 days (661)
Last 30 days (2736)
Last 365 days (30027)
2026 (7977)
2025 (30222)
2024 (35257)
2023 (40111)
2022 (51196)
2021 (55726)
2020 (54095)
2019 (46558)
2018 (35027)
2017 (32114)
2016 (31491)
2015 (37561)
2014 (31334)
2013 (26350)
2012 (28577)
2011 (29276)
2010 (27337)
Location
Africa (739)
Alabama (90)
Alaska (7)
Arizona (331)
Arkansas (13)
Asia (39475)
Australia (6467)
California (12248)
Canada (3508)
China (1226)
Colorado (522)
Connecticut (520)
Delaware (366)
Europe (85327)
Florida (1849)
Georgia (393)
Hawaii (3)
Idaho (62)
Illinois (954)
India (80)
Indiana (558)
Iowa (22)
Japan (486)
Kansas (129)
Kentucky (44)
Louisiana (38)
Maine (73)
Maryland (1481)
Massachusetts (8771)
Michigan (346)
Minnesota (674)
Mississippi (6)
Missouri (140)
Montana (33)
Nebraska (29)
Nevada (135)
New Hampshire (82)
New Jersey (3269)
New Mexico (28)
New York (3230)
North Carolina (1551)
North Dakota (8)
Northern California (6056)
Ohio (365)
Oklahoma (22)
Oregon (41)
Pennsylvania (2481)
Puerto Rico (26)
Rhode Island (50)
South America (1113)
South Carolina (76)
South Dakota (1)
Southern California (4812)
Tennessee (199)
Texas (1922)
United States (43406)
Utah (368)
Vermont (1)
Virginia (292)
Washington D.C. (80)
Washington State (980)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
726,562 Results for "avid radiopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
The deal, announced early Sunday afternoon, will see Novartis gain access to Avidity’s neuroscience assets, while the San Diego biotech spins out a new company to shepherd its early-stage precision cardiology programs.
October 26, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Avidity Played Hardball To Land Favorable Terms in $12B Novartis Deal
At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data room and moving on to a capital raise.
November 25, 2025
·
3 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
September 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
February 23, 2026
·
8 min read
Press Releases
Avidity Biosciences Announces Expected Record Date for Spin-Off
February 3, 2026
·
8 min read
Press Releases
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
March 1, 2026
·
4 min read
Press Releases
Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California
February 24, 2026
·
2 min read
Press Releases
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 26, 2026
·
3 min read
Press Releases
Avid Bioservices Appoints Rich McAvoy as Chief Business Officer
January 16, 2026
·
2 min read
Neurodegenerative disease
Avidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle Strength
Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the first disease-modifying treatment for facioscapulohumeral muscular dystrophy—with an application in the second half of 2026.
June 9, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 72,657
Next
